# Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL

Source: https://onco.cc/trials/nct01305655/  
OnCo record `nct01305655` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Glucarpidase in Acute lymphoblastic leukaemia, run by Nordic Society for Pediatric Hematology and Oncology, completed.

## Summary

Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL is a phase 3 interventional study registered as NCT01305655 by Nordic Society for Pediatric Hematology and Oncology, with 47 participants recorded, started 2008-07 and reaching its primary completion in 2014-12. Interventions recorded: Glucarpidase. Conditions recorded: Acute Lymphoblastic Leukemia (ALL).

Linked to the drug Glucarpidase because the registry names it among its interventions and Acute lymphoblastic leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01305655
- Phase: 3
- Setting: Glucarpidase (CPG2) Effect on Severe Delayed Methotrexate-clearance in Children Treated With High-dose Methotrexate in Acute Lymphoblastic Leukemia (ALL)
- Sponsor: Nordic Society for Pediatric Hematology and Oncology
- Enrolled: 47

## Sources

- ClinicalTrials.gov NCT01305655: https://clinicaltrials.gov/study/NCT01305655

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- drugs: [Glucarpidase](https://onco.cc/drugs/glucarpidase/)

---
JSON: https://onco.cc/api/v1/entities/nct01305655.json